Press Releases

12.12.2024

Pfizer Declares First-Quarter 2025 Dividend

12.12.2024

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

12.10.2024

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

12.10.2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

12.05.2024

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

11.20.2024

Pfizer Announces New Chief Scientific Officer and President, Research & Development

11.20.2024

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

11.14.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.04.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

10.29.2024

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

10.23.2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

10.22.2024

U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease